Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2017 | Research

FOXA1 inhibits hepatocellular carcinoma progression by suppressing PIK3R1 expression in male patients

Authors: Shujiao He, Junyi Zhang, Wan Zhang, Fengsheng Chen, Rongcheng Luo

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2017

Abstract

Background

Forkhead box A1 (FOXA1) expression is associated with various types of tumors; however, the function and underlying mechanism of FOXA1 in the development of hepatocellular carcinoma (HCC) remains obscure.

Methods

Here, we investigated the role of FOXA1 in the development of HCC by applying gene function gain and loss analysis to HepG2 and Hep3B cell lines, and comparing outcomes with those of clinical HCC samples.

Results

Phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1), which encodes protein PI3Kp85 (p85), was identified as a FOXA1 target gene. Analyses of the mechanism and function revealed that FOXA1 suppresses hepatocellular carcinoma cell viability and motility by inhibiting PI3K/Akt signaling through direct inhibition of PIK3R1 transcription. Moreover, in clinical samples from male HCC patients, FOXA1 expression was much lower, whereas PI3Kp85 levels were much higher in tumor than in non-tumor tissues. Elevated PI3Kp85 is an unfavorable factor in HCC.

Conclusions

As a tumor suppressor, FOXA1 targets PIK3R1 directly to inhibit PI3K/Akt signaling pathway, thus exerting a negative regulatory effect on proliferation, migration, and invasion of HCC in male patients.

Available only for authorised users

Faloppi L, Scartozzi M, Maccaroni E, Di Pietro PM, Berardi R, Del PM, Cascinu S. Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. Cancer Treat Rev. 2011;37:169–77.CrossRefPubMed

Liu Y, Song L, Ni H, Sun L, Jiao W, Chen L, Zhou Q, Shen T, Cui H, Gao T, Li J. ERBB4 acts as a suppressor in the development of hepatocellular carcinoma. Carcinogenesis. 2017;38:465–73.CrossRefPubMed

Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2016;

Jozwik KM, Carroll JS. Pioneer factors in hormone-dependent cancers. Nat Rev Cancer. 2012;12:381–5.CrossRefPubMed

Bochkis IM, Rubins NE, White P, Furth EE, Friedman JR, Kaestner KH. Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress. Nat Med. 2008;14(8):828–36.CrossRefPubMedPubMedCentral

Augello MA, Hickey TE, Knudsen KE. FOXA1: master of steroid receptor function in cancer. EMBO J. 2011;30:3885–94.CrossRefPubMedPubMedCentral

Mei S, Qin Q, Wu Q, Sun H, Zheng R, Zang C, Zhu M, Wu J, Shi X, Taing L, Liu T, Brown M, Meyer CA, Liu XS. Cistrome data browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse. Nucleic Acids Res. 2017;45:D658–62.CrossRefPubMed

Yang JH, Li JH, Jiang S, Zhou H, ChIPBase QLH. A database for decoding the transcriptional regulation of long non-coding RNA and microRNA genes from ChIP-Seq data. Nucleic Acids Res. 2012;41:D177–87.CrossRefPubMedPubMedCentral

Cao C, Sun J, Zhang D, Guo X, Xie L, Li X, Wu D, Liu L. The long intergenic noncoding RNA UFC1, a target of MicroRNA 34a, interacts with the mRNA stabilizing protein HuR to increase levels of beta-catenin in HCC cells. Gastroenterology. 2015;148:415–26.CrossRefPubMed

10.

Song Y, Washington MK, Crawford HC. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res. 2010;70:2115–25.CrossRefPubMedPubMedCentral

11.

Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, Carroll JS. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 2011;30:3019–27.CrossRefPubMedPubMedCentral

12.

Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J, Vesterinen T, Nordling S, Kallioniemi O, Hautaniemi S, Janne OA. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 2011;30:3962–76.CrossRefPubMedPubMedCentral

13.

Chen F, Chen GK, Millikan RC, John EM, Ambrosone CB, Bernstein L, Zheng W, JJ H, Ziegler RG, Deming SL, Bandera EV, Nyante S, Palmer JR, Rebbeck TR, Ingles SA, Press MF, Rodriguez-Gil JL, Chanock SJ, Le Marchand L, Kolonel LN, Henderson BE, Stram DO, Haiman CA. Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans. Hum Mol Genet. 2011;20:4491–503.CrossRefPubMedPubMedCentral

14.

Jin HJ, Zhao JC, Ogden I, Bergan RC, Yu J. Androgen Receptor-Independent function of FoxA1 in prostate cancer metastasis. Cancer Res. 2013;73:3725–36.CrossRefPubMedPubMedCentral

15.

Liu YN, Lee WW, Wang CY, Chao TH, Chen Y, Chen JH. Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene. 2005;24:8277–90.CrossRefPubMed

16.

Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, Qiu J, Liu W, Kaikkonen MU, Ohgi KA, Glass CK, Rosenfeld MG, Reprogramming FX. Transcription by distinct classes of enhancers functionally defined by eRNA. Nature. 2011;474:390–4.CrossRefPubMedPubMedCentral

17.

Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell. 2012;148:72–83.CrossRefPubMedPubMedCentral

18.

Kanamoto N, Tagami T, Ueda-Sakane Y, Sone M, Miura M, Yasoda A, Tamura N, Arai H, Nakao K. Forkhead box A1 (FOXA1) and A2 (FOXA2) oppositely regulate human type 1 iodothyronine deiodinase gene in liver. Endocrinology. 2012;153:492–500.CrossRefPubMed

19.

Manning BD, Cantley LCAKT. PKB signaling: navigating downstream. Cell. 2007;129:1261–74.CrossRefPubMedPubMedCentral

20.

Nandini D. Pradip, Brian LJ. PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials. Pharmacol Ther. 2017;

21.

Khotskaya YB. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017;173:58–66.

22.

Fritsch R, Downward J. SnapShot: class I PI3K isoform signaling. Cell. 2013;154:940.CrossRefPubMed

23.

Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: eastern cooperative oncology group E2303. Clin Cancer Res. 2014;20:3023–32.CrossRefPubMedPubMedCentral

24.

Yu W, Honisch S, Schmidt S, Yan J, Schmid E, Alkahtani S, AlKahtane AA, Alarifi S, Stournaras C, Lang F. Chorein sensitive Orai1 expression and store operated Ca2+ entry in rhabdomyosarcoma cells. Cell Physiol Biochem. 2016;40:1141–52.CrossRefPubMed

Title: FOXA1 inhibits hepatocellular carcinoma progression by suppressing PIK3R1 expression in male patients
Authors: Shujiao He
Junyi Zhang
Wan Zhang
Fengsheng Chen
Rongcheng Luo
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2017
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-017-0646-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

MIF/CD74 axis is a target for novel therapies in colon carcinomatosis

Inhibition of EGR1 inhibits glioma proliferation by targeting CCND1 promoter

Smoldering mantle cell lymphoma

RETRACTED ARTICLE: TGF-β2 initiates autophagy via Smad and non-Smad pathway to promote glioma cells’ invasion

Long non-coding RNA NKILA inhibits migration and invasion of non-small cell lung cancer via NF-κB/Snail pathway

Regulation of TRIM24 by miR-511 modulates cell proliferation in gastric cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer